Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Very informative piece on Intercept and Nash
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(200)
•••
Comment by palinc2000on Apr 28, 2023 10:07am
63 Views
Post# 35418999

RE:Very informative piece on Intercept and Nash

RE:Very informative piece on Intercept and NashAbout the author

As a Registered Nurse with a Bachelor of Science in Nursing (BSN), I am deeply dedicated to maintaining a strong focus on biotechnology, consistently seeking to stay up-to-date with the latest treatment recommendations and market trends. This commitment is fueled by my passion for the field and further strengthened by my extensive professional experience.Having had significant interactions with patients, I possess a unique ability to detect subtle details that may be missed by individuals who lack direct clinical experience. Drawing upon my analytical skills, I am able to offer valuable insights and perspectives on biotechnology-related topics, synthesizing my extensive knowledge and experience in this field to produce comprehensive, research-driven written materials.

One has to be impressed with the content of most of the 21 comments .....most looking for facts and not a bunch of moaners and ranters



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities